⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2225500 | 0.77 | — | — | |
| SCHEMBL1196146 | 0.73 | — | — | |
| SCHEMBL2221072 | 0.72 | GABRP (0.39) | — | |
| SCHEMBL2914761 | 0.71 | — | — | |
| SCHEMBL5634709 | 0.69 | — | — | |
| SCHEMBL8673 | 0.69 | — | — | |
| SCHEMBL23366184 | 0.67 | CYP2C19 (0.50) | — | |
| SCHEMBL375124 | 0.67 | CYP2C19 (0.50) | — | |
| SCHEMBL8204743 | 0.67 | CYP2C19 (0.50) | — | |
| Cyclopropane Carboxylic Acid SCHEMBL4643 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115413275-A | Substituted 1,1 , -biphenyl compounds and methods of use thereof | 爱彼特生物制药公司 | 2022-11-29 | — | — | CN | claimed |
| US-20220213090-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2022-07-07 | — | — | US | claimed |
| EP-3558963-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS IMMUNOMODULATORS | Incyte Corporation (US) | 2019-10-30 | — | — | EP | claimed |
| US-20180179202-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-06-28 | — | — | US | claimed |
| WO-2018119286-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2018-06-28 | — | — | WO | claimed |
| JP-2007506696-A | — | — | 2007-03-22 | — | — | JP | claimed |
| US-20070060582-A1 | 1,4-Disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases | FINK CYNTHIA A | 2007-03-15 | — | — | US | claimed |
| EP-1667980-A1 | 1,4-DISUBSTITUTED ISOQUINOLINE DERIVATIVES AS RAF-KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis AG (CH) | 2006-06-14 | — | — | EP | claimed |
| WO-2005028444-A1 | 1,4-DISUBSTITUTED ISOQUINILONE DERIVATIVES AS RAF-KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2005-03-31 | — | — | WO | claimed |
| CN-115413275-A | Substituted 1,1 , -biphenyl compounds and methods of use thereof | 爱彼特生物制药公司 | 2022-11-29 | — | — | CN | disclosed |
| US-20220213090-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2022-07-07 | — | — | US | disclosed |
| EP-3558963-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS IMMUNOMODULATORS | Incyte Corporation (US) | 2019-10-30 | — | — | EP | disclosed |
| US-20180179202-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-06-28 | — | — | US | disclosed |
| WO-2018119286-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2018-06-28 | — | — | WO | disclosed |
| EP-1591443-A1 | PYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-02 | — | — | EP | disclosed |
| WO-2005028444-A1 | 1,4-DISUBSTITUTED ISOQUINILONE DERIVATIVES AS RAF-KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2005-03-31 | — | — | WO | disclosed |
| US-4323568-A | INHIBIT PLATELET AGGREGATION | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) | 1982-04-06 | — | — | US | disclosed |
| EP-0001759-B1 | (OMEGA-AMINOALKOXY) BIBENZYLS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE SUBSTANCES | MITSUBISHI KASEI CORPORATION (JP) | 1981-12-30 | — | — | EP | disclosed |
| US-4220603-A | ANTICOAGULANTS | MITSUBISHI CHEMICAL INDUSTRIES, LIMITED (JP) | 1980-09-02 | — | — | US | disclosed |
| EP-0001759-A1 | (Omega-aminoalkoxy) bibenzyls, processes for their preparation and pharmaceutical compositions containing these substances | MITSUBISHI KASEI CORPORATION (JP) | 1979-05-16 | — | — | EP | disclosed |